Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With and Without FLT3-ITD Activating Mutations

Trial Profile

Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With and Without FLT3-ITD Activating Mutations

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2017

At a glance

  • Drugs Quizartinib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms ACE
  • Sponsors Ambit Biosciences Corporation; Daiichi Sankyo Inc
  • Most Recent Events

    • 25 Jun 2017 Results (n=176) of a landmark analysis on the pooled sample of the AC220-002 and NCRI cohorts to compare survival between transplanted and non-transplanted patients, presented at the 22nd Congress of the European Haematology Association
    • 10 Jun 2017 Biomarkers information updated
    • 15 Aug 2013 SEE TRIAL COMMENT, THIS TRIAL MAY BE REGISTRATIONAL
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top